Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NYSE:EBS
- CUSIP: 29089Q10
- Web: www.emergentbiosolutions.com
Capitalization:- Market Cap: $1.4296 billion
- Outstanding Shares: 40,974,000
Average Prices:- 50 Day Moving Avg: $33.28
- 200 Day Moving Avg: $31.00
- 52 Week Range: $24.47 - $36.64
P/E:- Trailing P/E Ratio: 28.65
- Foreward P/E Ratio: 18.77
- P/E Growth: 1.35
Sales & Book Value:- Annual Revenue: $502.68 million
- Price / Sales: 2.94
- Book Value: $14.90 per share
- Price / Book: 2.42
Profitability:- EBIDTA: $150.22 million
- Net Margins: 10.36%
- Return on Equity: 11.92%
- Return on Assets: 7.40%
Debt:- Debt-to-Equity Ratio: 0.41%
- Current Ratio: 7.23%
- Quick Ratio: 6.18%
Misc:- Average Volume: 292,460 shs.
- Beta: 1.21
- Short Ratio: 8.64
Frequently Asked Questions for Emergent Biosolutions (NYSE:EBS)
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions, Inc. (NYSE:EBS) announced its earnings results on Thursday, May, 4th. The company reported $0.23 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.31 by $0.08. The firm had revenue of $116.90 million for the quarter, compared to the consensus estimate of $121.30 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. Emergent Biosolutions's revenue for the quarter was up 13.5% on a year-over-year basis. During the same quarter last year, the business posted $0.16 EPS. View Emergent Biosolutions' Earnings History.
Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?
4 brokerages have issued 1 year target prices for Emergent Biosolutions' shares. Their predictions range from $33.00 to $47.00. On average, they anticipate Emergent Biosolutions' stock price to reach $39.25 in the next twelve months. View Analyst Ratings for Emergent Biosolutions.
What are analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
- 1. According to Zacks Investment Research, "Emergent’s key drug BioThrax is from the company’s Biodefense segment. The U.S. government is the primary purchaser of its Biodefense products. Hence, the company’s sole dependence on BioThrax for its revenue is concerning. Moreover, Emergent faces competition from a number of companies with Biodefense products, which could adversely affect the company’s operating results. Shares of the company have underperformed the broader industry so far this year. However, the company’s follow-on contract with the CDC for BioThrax and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/17/2017)
- 2. Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)
- 3. J P Morgan Chase & Co analysts commented, "This afternoon, Emergent announced 2Q financial results, and while a great deal of focus remains on the upcoming BioThrax and NuThrax contracts, details were limited on these topics and 2016 guidance will not be reinstated until the outcomes are known. While we continue to see high probability of approval for Building 55 (Aug 15 PDUFA date), we believe the Street will need incremental clarity, particularly visibility on pricing in the next BioThrax contract and some color on expectations for the near-term delivery schedule, for the overhang on EBS shares to begin to lift. That said, this clarity is not far off, and we expect an update on both BioThrax and NuThrax by the end of September." (8/5/2016)
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Intrexon Corporation (XON), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals Incorporated (LGND), FibroGen (FGEN), Blueprint Medicines Corporation (BPMC), Foundation Medicine (FMI), Momenta Pharmaceuticals (MNTA), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Genus plc (GNS), Esperion Therapeutics (ESPR), Immunomedics (IMMU), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Heron Therapeutics (HRTX), Biohaven Pharmaceutical Holding Co Ltd (BHVN) and Arena Pharmaceuticals (ARNA).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Fuad El-Hibri, Executive Chairman of the Board
- Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director
- Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer
- Adam Havey, Executive Vice President - Business Operations
- Ronald B. Richard, Lead Independent Director
- Sue Bailey M.D., Independent Director
- Zsolt Harsanyi Ph.D., Independent Director
- Jerome M. Hauer, Independent Director
- George A. Joulwan USA, Independent Director
Who owns Emergent Biosolutions stock?
Emergent Biosolutions' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.97%), Peregrine Capital Management LLC (0.79%), Bank of Montreal Can (0.21%), US Bancorp DE (0.10%), Eqis Capital Management Inc. (0.09%) and Nisa Investment Advisors LLC (0.09%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?
Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC, Peregrine Capital Management LLC, Capstone Asset Management Co., Nisa Investment Advisors LLC and US Bancorp DE. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Jerome M Hauer, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.
Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?
Emergent Biosolutions' stock was acquired by a variety of institutional investors in the last quarter, including Capital Asset Advisory Services LLC, State of Alaska Department of Revenue, Aperio Group LLC, Eqis Capital Management Inc., Louisiana State Employees Retirement System and Creative Planning. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy Emergent Biosolutions stock?
Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of Emergent Biosolutions stock can currently be purchased for approximately $36.04.
MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Emergent Biosolutions (NYSE:EBS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $39.25 (8.91% upside) |
Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/30/2017 | Chardan Capital | Reiterated Rating | Buy | $47.00 | N/A |  |
| 1/9/2017 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 10/1/2016 | Wells Fargo & Company | Set Price Target | Buy | $41.00 | N/A | |
| 8/5/2016 | J P Morgan Chase & Co | Lower Price Target | Overweight | $45.00 -> $36.00 | N/A | |
| 6/28/2016 | Singular Research | Lower Price Target | Buy | $44.00 -> $40.00 | N/A | |
(Data available from 7/21/2015 forward)
Earnings History for Emergent Biosolutions (NYSE:EBS)Earnings History by Quarter for Emergent Biosolutions (NYSE EBS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | $0.31 | $0.23 | $121.30 million | $116.90 million | View | Listen | |
| 2/23/2017 | Q4 2016 | $0.48 | $0.74 | $120.45 million | $151.66 million | View | Listen | |
| 11/7/2016 | Q3 | $0.26 | $0.58 | $112.30 million | $142.91 million | View | Listen | |
| 8/4/2016 | Q2 | ($0.17) | ($0.18) | $111.20 million | $101.49 million | View | Listen | |
| 5/5/2016 | Q1 | ($0.07) | $0.16 | $101.83 million | $111.00 million | View | Listen | |
| 2/25/2016 | Q4 | $0.69 | $0.78 | $168.07 million | $168.10 million | View | Listen | |
| 11/5/2015 | Q315 | $0.55 | $0.83 | $151.42 million | $164.90 million | View | Listen | |
| 8/6/2015 | Q215 | $0.18 | $0.36 | $114.25 million | $126.10 million | View | Listen | |
| 5/7/2015 | Q1 | ($0.46) | ($0.50) | $62.70 million | $63.60 million | View | Listen | |
| 3/5/2015 | Q115 | $0.97 | $0.75 | $147.00 million | $148.00 million | View | Listen | |
| 11/6/2014 | Q414 | $0.37 | $0.67 | $126.90 million | $138.00 million | View | Listen | |
| 8/7/2014 | Q214 | $0.26 | $0.24 | $109.25 million | $110.30 million | View | Listen | |
| 5/8/2014 | Q114 | ($0.34) | ($0.40) | $57.30 million | $53.90 million | View | Listen | |
| 3/6/2014 | Q413 | $0.36 | $0.42 | $93.83 million | $94.10 million | View | Listen | |
| 11/7/2013 | Q313 | $0.21 | $0.37 | $79.13 million | $89.10 million | View | Listen | |
| 8/5/2013 | Q2 2013 | $0.21 | $0.29 | $75.73 million | $82.40 million | View | Listen | |
| 5/2/2013 | Q1 2013 | ($0.14) | ($0.22) | $46.17 million | $43.10 million | View | Listen | |
| 3/7/2013 | Q4 2012 | $0.44 | $0.44 | $95.09 million | $94.61 million | View | Listen | |
| 11/1/2012 | Q312 | $0.22 | $0.18 | $73.53 million | $66.60 million | View | N/A | |
| 8/2/2012 | | $0.21 | $0.21 | | | View | N/A | |
| 5/3/2012 | | ($0.18) | ($0.19) | | | View | N/A | |
| 3/8/2012 | | $0.72 | $0.78 | | | View | N/A | |
| 11/3/2011 | | ($0.04) | $0.04 | | | View | N/A | |
| 8/4/2011 | | $0.33 | $0.40 | | | View | N/A | |
| 5/5/2011 | | ($0.52) | ($0.64) | | | View | N/A | |
| 3/10/2011 | | $0.67 | $0.76 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Emergent Biosolutions (NYSE:EBS)Current Year EPS Consensus Estimate: $1.51 EPS
Next Year EPS Consensus Estimate: $1.92 EPS
Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Emergent Biosolutions (NYSE:EBS)Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 85.89%
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/3/2017 | Adam Havey | EVP | Sell | 11,419 | $28.62 | $326,811.78 | |
| 3/8/2017 | Jerome M Hauer | Director | Sell | 2,576 | $31.27 | $80,551.52 | |
| 1/17/2017 | Adam Havey | EVP | Sell | 8,438 | $29.75 | $251,030.50 | |
| 1/17/2017 | Sue Bailey | Director | Sell | 19,424 | $29.78 | $578,446.72 | |
| 1/10/2017 | Daniel Abdun-Nabi | Insider | Sell | 28,240 | $31.28 | $883,347.20 | |
| 12/13/2016 | Ronald Richard | Director | Sell | 5,900 | $34.09 | $201,131.00 | |
| 6/6/2016 | George A Joulwan | Director | Sell | 4,700 | $44.12 | $207,364.00 | |
| 6/1/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,699 | $43.74 | $380,494.26 | |
| 5/27/2016 | Fuad El-Hibri | Major Shareholder | Sell | 9,835 | $43.50 | $427,822.50 | |
| 5/26/2016 | Fuad El-Hibri | Major Shareholder | Sell | 39,759 | $43.13 | $1,714,805.67 | |
| 5/25/2016 | Fuad El-Hibri | Major Shareholder | Sell | 85,000 | $42.52 | $3,614,200.00 | |
| 5/25/2016 | Zsolt Harsanyi | Director | Sell | 27,867 | $42.33 | $1,179,610.11 | |
| 5/24/2016 | Fuad El-Hibri | Chairman | Sell | 20,000 | $42.26 | $845,200.00 | |
| 5/23/2016 | Fuad El-Hibri | Chairman | Sell | 45,000 | $42.62 | $1,917,900.00 | |
| 5/20/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,701 | $42.00 | $365,442.00 | |
| 5/19/2016 | Jerome M Hauer | Director | Sell | 3,134 | $41.22 | $129,183.48 | |
| 5/13/2016 | Louis W Sullivan | Director | Sell | 47,631 | $39.21 | $1,867,611.51 | |
| 5/12/2016 | Fuad El-Hibri | Major Shareholder | Sell | 25,000 | $38.71 | $967,750.00 | |
| 5/12/2016 | Jerome M Hauer | Director | Sell | 4,700 | $38.50 | $180,950.00 | |
| 5/11/2016 | Louis W Sullivan | Director | Sell | 9,969 | $39.25 | $391,283.25 | |
| 4/22/2016 | Fuad El-Hibri | Major Shareholder | Sell | 4,209 | $40.50 | $170,464.50 | |
| 4/18/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,702 | $40.17 | $349,559.34 | |
| 4/18/2016 | Fuad El-Hibri | Major Shareholder | Sell | 20,791 | $40.50 | $842,035.50 | |
| 4/6/2016 | Fuad El-Hibri | Major Shareholder | Sell | 50,000 | $39.00 | $1,950,000.00 | |
| 4/6/2016 | Robert Kramer | EVP | Sell | 21,786 | $38.90 | $847,475.40 | |
| 4/4/2016 | Robert Kramer | EVP | Sell | 21,788 | $36.90 | $803,977.20 | |
| 4/1/2016 | Robert Kramer | EVP | Sell | 43,572 | $35.56 | $1,549,420.32 | |
| 3/14/2016 | Adam Havey | EVP | Sell | 4,359 | $33.96 | $148,031.64 | |
| 3/14/2016 | Jerome M Hauer | Director | Sell | 2,350 | $33.88 | $79,618.00 | |
| 3/11/2016 | Adam Havey | EVP | Sell | 11,112 | $33.84 | $376,030.08 | |
| 3/11/2016 | Louis W Sullivan | Director | Sell | 14,879 | $34.03 | $506,332.37 | |
| 3/7/2016 | Marvin L White | Director | Sell | 33,134 | $35.42 | $1,173,606.28 | |
| 1/4/2016 | Sue Bailey | Director | Sell | 11,520 | $38.79 | $446,860.80 | |
| 12/30/2015 | Ronald Richard | Director | Sell | 21,600 | $40.00 | $864,000.00 | |
| 12/24/2015 | Daniel Abdun-Nabi | CEO | Sell | 63,209 | $39.06 | $2,468,943.54 | |
| 11/19/2015 | Fuad El-Hibri | major shareholder | Sell | 17,871 | $37.50 | $670,162.50 | |
| 11/13/2015 | Fuad El-Hibri | major shareholder | Sell | 13,013 | $36.50 | $474,974.50 | |
| 11/12/2015 | Barry Labinger | EVP | Sell | 36,126 | $35.64 | $1,287,530.64 | |
| 11/9/2015 | Fuad El-Hibri | major shareholder | Sell | 13,225 | $35.50 | $469,487.50 | |
| 11/6/2015 | Fuad El-Hibri | major shareholder | Sell | 13,450 | $34.50 | $464,025.00 | |
| 11/3/2015 | Fuad El-Hibri | major shareholder | Sell | 13,689 | $33.50 | $458,581.50 | |
| 9/11/2015 | Sue Bailey | Director | Sell | 6,080 | $32.37 | $196,809.60 | |
| 8/13/2015 | George A Joulwan | Director | Sell | 7,200 | $34.72 | $249,984.00 | |
| 7/20/2015 | Fuad El-Hibri | Chairman | Sell | 234 | $34.50 | $8,073.00 | |
| 7/13/2015 | Ronald Richard | Director | Sell | 4,922 | $34.00 | $167,348.00 | |
| 6/29/2015 | Ronald Richard | Director | Sell | 4,923 | $32.76 | $161,277.48 | |
| 6/22/2015 | Fuad El-Hibri | Major Shareholder | Sell | 74,564 | $32.60 | $2,430,786.40 | |
| 6/16/2015 | Louis W Sullivan | Director | Sell | 13,457 | $31.33 | $421,607.81 | |
| 6/15/2015 | Adam Havey | EVP | Sell | 36,298 | $31.55 | $1,145,201.90 | |
| 6/15/2015 | Fuad El-Hibri | Major Shareholder | Sell | 45,436 | $32.18 | $1,462,130.48 | |
| 1/20/2015 | Fuad El-Hibri | Major Shareholder | Sell | 15,325 | $27.67 | $424,042.75 | |
| 12/26/2014 | Ronald Richard | Director | Sell | 5,000 | $28.00 | $140,000.00 | |
| 12/17/2014 | Ronald Richard | Director | Sell | 5,000 | $27.00 | $135,000.00 | |
| 12/11/2014 | Fuad El-Hibri | Major Shareholder | Sell | 119,341 | $26.00 | $3,102,866.00 | |
| 11/28/2014 | Fuad El-Hibri | Major Shareholder | Sell | 34,577 | $25.00 | $864,425.00 | |
| 11/25/2014 | Fuad El-Hibri | Major Shareholder | Sell | 9,014 | $25.00 | $225,350.00 | |
| 11/25/2014 | Zsolt Harsanyi | Director | Sell | 8,000 | $24.82 | $198,560.00 | |
| 11/12/2014 | Fuad El-Hibri | Major Shareholder | Sell | 2,311 | $25.00 | $57,775.00 | |
| 11/7/2014 | Robert Kramer | CFO | Sell | 2,625 | $24.00 | $63,000.00 | |
| 4/16/2014 | Robert Kramer | CFO | Sell | 50,189 | $24.34 | $1,221,600.26 | |
| 3/12/2014 | Adam Havey | EVP | Sell | 11,562 | $27.50 | $317,955.00 | |
| 3/11/2014 | Adam Havey | EVP | Sell | 17,655 | $26.96 | $475,978.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Emergent Biosolutions (NYSE:EBS)
Latest Headlines for Emergent Biosolutions (NYSE:EBS)
| Source: |
|
| Date | Headline |
|---|
 | Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 3:25 PM |
 | Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
finance.yahoo.com - July 20 at 3:25 PM |
| Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
finance.yahoo.com - July 19 at 9:18 PM |
 | Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
www.zacks.com - July 17 at 7:01 PM |
| Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
finance.yahoo.com - July 17 at 7:01 PM |
 | Emergent Biosolutions, Inc. (EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:26 PM |
 | Emergent BioSolutions To Buy ACAM2000 Business From Sanofi For Up To $125 Mln
www.rttnews.com - July 16 at 5:28 PM |
| Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi - GlobeNewswire (press release)
globenewswire.com - July 14 at 4:09 PM |
| Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi
finance.yahoo.com - July 14 at 4:09 PM |
| Emergent acquires Sanofi smallpox vaccine in deal worth up to $125 million
finance.yahoo.com - July 14 at 4:09 PM |
| Emergent Biosolutions, Inc. (EBS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 10:53 AM |
| Emergent Biosolutions, Inc. (EBS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - June 24 at 7:20 PM |
 | Why Is Emergent Biosolutions (EBS) Up 3.9% Since the Last ... - Nasdaq
www.nasdaq.com - June 9 at 5:19 PM |
| Why Is Emergent Biosolutions (EBS) Up 3.9% Since the Last Earnings Report?
finance.yahoo.com - June 9 at 5:19 PM |
| ETFs with exposure to Emergent BioSolutions, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 5:15 PM |
| Noteworthy Tuesday Option Activity: EBS, WNR, LNG
www.nasdaq.com - May 30 at 4:45 PM |
| Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : May 24, 2017
finance.yahoo.com - May 24 at 12:25 PM |
| EBS Crosses Below Key Moving Average Level
www.nasdaq.com - May 22 at 4:37 PM |
 | Emergent BioSolutions (EBS) Presents At Three Part Advisors 2017 East Coast IDEAS Investor Conference - Slideshow
seekingalpha.com - May 22 at 4:37 PM |
| ETFs with exposure to Emergent BioSolutions, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:37 PM |
| Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 4:42 PM |
| Emergent Biosolutions Inc (EBS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 16 at 8:58 AM |
| Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in ... - GlobeNewswire (press release)
globenewswire.com - May 11 at 10:38 PM |
| Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore
finance.yahoo.com - May 10 at 5:01 PM |
| Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
finance.yahoo.com - May 9 at 7:19 AM |
| Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 8 at 4:45 PM |
 | Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth
www.fool.com - May 8 at 4:34 PM |
| Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : May 8, 2017
finance.yahoo.com - May 8 at 9:19 AM |
| Edited Transcript of EBS earnings conference call or presentation 4-May-17 9:00pm GMT
finance.yahoo.com - May 5 at 5:04 PM |
| Emergent Biosolutions Inc (EBS) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 12:00 AM |
 | Emergent Biosolutions beats 1Q profit forecasts
marketbeat.com - May 4 at 7:17 PM |
| Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
finance.yahoo.com - May 4 at 5:01 PM |
| Emergent Biosolutions (EBS) Getting Very Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 7:39 AM |
| Emergent BioSolutions, Inc. – Value Analysis (NYSE:EBS) : April 27, 2017
finance.yahoo.com - April 27 at 5:25 PM |
| Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : April 26, 2017
finance.yahoo.com - April 26 at 11:54 PM |
| Emergent Biosolutions (EBS) Earns Coverage Optimism Score of -0.22
www.americanbankingnews.com - April 25 at 12:03 PM |
| Emergent Biosolutions (EBS) Receiving Positive News Coverage, Report Shows
www.americanbankingnews.com - April 22 at 2:49 PM |
| Emergent Biosolutions Inc (EBS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 21 at 9:47 AM |
| Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017 - GlobeNewswire (press release)
globenewswire.com - April 20 at 8:38 AM |
| Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
finance.yahoo.com - April 20 at 8:38 AM |
| Emergent Biosolutions (EBS) Receiving Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 16 at 9:08 AM |
| Insider Selling: Emergent Biosolutions Inc (EBS) EVP Sells 11,419 Shares of Stock
www.americanbankingnews.com - April 4 at 8:37 PM |
| Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin - GlobeNewswire (press release)
globenewswire.com - April 2 at 8:36 AM |
 | Emergent BioSolutions (EBS) Agrees to $53M BARDA Contract Modification for Supply of Botulism Antitoxin - StreetInsider.com
www.streetinsider.com - April 1 at 8:36 AM |
 | Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
us.rd.yahoo.com - March 31 at 4:57 PM |
| Emergent Biosolutions Inc (EBS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 27 at 1:08 PM |
| Emergent BioSolutions: Underlying Value To Be Realized Following Aptevo Spin-Off
seekingalpha.com - March 26 at 10:02 AM |
 | Emergent BioSolutions Inc. (NYSE: EBS) gets $100 million anthrax ... - Washington Business Journal
www.bizjournals.com - March 20 at 7:44 PM |
| Emergent BioSolutions gets $100 million anthrax contract from feds
www.bizjournals.com - March 20 at 7:44 PM |
| Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile - GlobeNewswire (press release)
globenewswire.com - March 19 at 4:30 PM |
Emergent Biosolutions (EBS) Chart for Friday, July, 21, 2017
